Business Context and Reporting Period
This Form 8-K is filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) for the reporting period ending December 31, 2009. The filing addresses a specific "Other Event" (Item 8.01) regarding a failed capital raise transaction.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to a specific subscription agreement:
- Agreed Purchase Price: $0.5217 per share.
- Total Shares Agreed: 1,916,811 shares.
- Total Agreed Consideration: $1,000,000 (split into two $500,000 tranches).
- Warrant Terms: Option to purchase 1,333,334 shares at $0.80 per share (subject to reduction if the second tranche was not paid).
- Cash Received: $0 as of December 31, 2009.
Material Changes and Transaction Status
On November 29, 2009, the Company entered into a subscription agreement with Jinke Group (Hong Kong) Ltd. The agreement required the Investor to wire $500,000 immediately for the first tranche of shares and an additional $500,000 by December 20, 2009, for the second tranche. As of the report date (December 31, 2009), the Company has not received payment for either the First Sale or the Second Sale. Consequently, the Company has not issued any shares or warrants under this agreement.
Outlook, Management Commentary, and Risks
Management Commentary: The Company has been informed by the Investor that the terms of the subscription agreement will be honored in full as quickly as possible. Management is actively working with the Investor to ensure compliance.
Risks and Contingencies: The primary risk is the failure of the Investor to fulfill the payment obligations, which would result in no capital infusion from this transaction. The warrant issuance is contingent upon the completion of the Second Sale; failure to pay by the deadline would have reduced the warrant shares by half, though the filing notes no payment has been made at all.
Investor Verification Checklist
- Verify if the $1,000,000 subscription agreement with Jinke Group has been fulfilled or terminated since December 31, 2009.
- Confirm the Company's current cash position and liquidity status given the failure to receive the expected capital.
- Check for subsequent filings regarding the status of the Investor or any legal actions taken to enforce the agreement.
- Review the Company's most recent 10-K or 10-Q for actual revenue and operating expense data, as this 8-K contains none.